Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07175285 · ClinicalTrials.gov registry record

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

A clinical trial of Systemic Lupus Erythematosus (SLE), sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
223
Enrollment target
20
Study locations

NCT07175285 is a study of Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 223 participants, below the 1,049-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07175285, a study of Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
223 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

Conditions Studied

Systemic Lupus Erythematosus (SLE)

Interventions

  • DRUG Current standard of care treatment options

Study Locations (20)

Florida

  • Local Institution - 0063 - Fort Lauderdale
  • Local Institution - 0061 - Hollywood
  • LIFE Clinical Trials - Margate
  • Local Institution - 0068 - Palm Beach Gardens

California

  • Local Institution - 0054 - La Jolla
  • Local Institution - 0001 - La Palma
  • Rheumatology Center of San Diego - San Diego

Michigan

  • Local Institution - 0034 - Ann Arbor
  • AA MRC - Grand Blanc

North Carolina

  • DJL Clinical Research, PLLC - Charlotte
  • Local Institution - 0037 - Durham

Arizona

  • Local Institution - 0062 - Mesa

Illinois

  • Local Institution - 0065 - Willowbrook

Maryland

  • Local Institution - 0064 - Rockville

New Jersey

  • Local Institution - 0060 - West Long Branch

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2025-10-08
Est. Completion 2032-11-01

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07175285

The ClinicalTrials.gov registry entry for NCT07175285 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,049-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (79% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which Current standard of care treatment options is the first listed.

NCT07175285 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT07175285 about?

NCT07175285 is a clinical study titled "A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants". The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

What is the current status of trial NCT07175285?

This trial is currently recruiting. The enrollment target is 223 participants. The study started on 2025-10-08. Estimated completion is 2032-11-01.

What conditions does trial NCT07175285 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).

What interventions are being tested in trial NCT07175285?

The interventions under investigation include: Current standard of care treatment options (DRUG).

Who is sponsoring clinical trial NCT07175285?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07175285 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus (SLE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus (SLE)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.